Question 1

What is Oncology Research?

Accepted Answer

Oncology Research (oncologyresearch.us) is a free web platform that provides healthcare professionals, researchers, and students with real-time access to peer-reviewed cancer research articles from PubMed, enhanced with AI-powered summarization, clinical trial cross-referencing from ClinicalTrials.gov, and personal research management tools.

Question 2

What cancer types does Oncology Research cover?

Accepted Answer

The platform provides focused filtering for breast cancer, lung cancer, brain cancer (glioblastoma, CNS tumors), leukemia (ALL, AML, CLL, CML), lymphoma (Hodgkin and Non-Hodgkin), prostate cancer, and colorectal cancer, while also supporting searches across all cancer types indexed in PubMed.

Question 3

Where does Oncology Research get its article data?

Accepted Answer

All article data is sourced in real-time from PubMed's E-utilities API operated by the U.S. National Library of Medicine at the National Institutes of Health. Clinical trial data comes from the ClinicalTrials.gov API. The platform does not publish original research.

Question 4

What AI features does Oncology Research offer?

Accepted Answer

Oncology Research uses Google Gemini 2.5 Flash to generate plain-language summaries of complex research abstracts with one click. The platform also provides oncology-specific search autocomplete suggestions, smart keyword-based related article discovery, and automated clinical trial matching from ClinicalTrials.gov.

Question 5

How do I cite articles found on Oncology Research?

Accepted Answer

Each article page provides one-click citation export in BibTeX, RIS, APA, and MLA formats. You can also bulk export your entire bookmark library in CSV, BibTeX, or RIS format. When citing specific research findings, cite the original article using its PMID or DOI.

Oncology Research

Dalmelitinib Plus Aumolertinib Improves Progression-Free Survival Over Platinum Chemotherapy (6.2 vs 4.4 Months) in EGFR-Mutated, MET-Amplified NSCLC After EGFR-TKI Progression, With Overall Survival Still Immature: A Randomized, Open-Label Phase 3 Trial